Clinical trial · Observational
The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
The Influence of Secretin Stimulated Pancreatic Secretion on Circulating Tumor DNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to assess the influence of pancreatic secretion stimulation by intravenously administered secretin on circulating tumor DNA in patients with pancreatic ductal adenocarcinoma. Additional aim of the study is to analyse a role of specific biomarkers in determining the prognosis of this disease. The main question o answer is: Does intravenous secretin administration potentiate the release of circulating tumor DNA in patients with pancreatis ductal adenocarcinoma? Additional question is: Is there a biomarker specific and sensitive enough to help to predict the prognosis and the at the time status of the disease? Participants scheduled for surgical treament due to pancreatic ductal adenocarcinoma will be included and stimulated with intravenously administered secretin, their peripheral blood samples will then be analyzed for ctDNA levels.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intravenously administered secretin | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with pancreatic ductal adenocarcinoma scheduled for surgery
- description
- Both male and female patients of all age diagnosed with pancreatic ductal adenocarcinoma and indicated for surgical treatment by multidisciplinary tumor board. Patients with and without previously completed chemotherapy will be included.
- interventionNames
- Other: Intravenously administered secretin
Primary outcomes (1)
- measure
- Plasmatic level of circulating tumor DNA
- timeFrame
- During the surgery: 3, 8, 13, 18 minutes after secretin administration; 3, 6 and 12 months after surgery
- description
- ng/ml
Secondary outcomes (1)
- measure
- Plasmatic levels of mRNA, miRNA, S100 proteins, siRNA, exoRNA.
- timeFrame
- During the surgery: 3, 8, 13, 18 minutes after secretin administration; 3, 6 and 12 months after surgery.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients diagnosed with pancreatic ductal adenocarcinoma * patients indicated for surgery by multidisciplinary tumor board * patients without previously administered chemotherapy * patients with previously administered chemotherapy Exclusion Criteria: * patients diagnosed with pancreatic ductal adenocarcinoma, at the time indicated for different than surgical therapy
References
Publications (12)
- BACKGROUNDSarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020 Feb 15;12(2):173-181. doi: 10.4251/wjgo.v12.i2.173. PMID 32104548
- BACKGROUNDUshio J, Kanno A, Ikeda E, Ando K, Nagai H, Miwata T, Kawasaki Y, Tada Y, Yokoyama K, Numao N, Tamada K, Lefor AK, Yamamoto H. Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics (Basel). 2021 Mar 20;11(3):562. doi: 10.3390/diagnostics11030562. PMID 33804776
- BACKGROUNDKamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016 Jul 2;388(10039):73-85. doi: 10.1016/S0140-6736(16)00141-0. Epub 2016 Jan 30. PMID 26830752
- BACKGROUNDImaoka H, Shimizu Y, Senda Y, Natsume S, Mizuno N, Hara K, Hijioka S, Hieda N, Tajika M, Tanaka T, Ishihara M, Niwa Y, Yamao K. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Pancreatology. 2016 Jul-Aug;16(4):658-64. doi: 10.1016/j.pan.2016.04.007. Epub 2016 Apr 22. PMID 27178104
- BACKGROUNDO'Neill RS, Stoita A. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J Gastroenterol. 2021 Jul 14;27(26):4045-4087. doi: 10.3748/wjg.v27.i26.4045. PMID 34326612
- BACKGROUNDTuranli B, Yildirim E, Gulfidan G, Arga KY, Sinha R. Current State of "Omics" Biomarkers in Pancreatic Cancer. J Pers Med. 2021 Feb 14;11(2):127. doi: 10.3390/jpm11020127. PMID 33672926
- BACKGROUNDWolrab D, Jirasko R, Cifkova E, Horing M, Mei D, Chocholouskova M, Peterka O, Idkowiak J, Hrnciarova T, Kuchar L, Ahrends R, Brumarova R, Friedecky D, Vivo-Truyols G, Skrha P, Skrha J, Kucera R, Melichar B, Liebisch G, Burkhardt R, Wenk MR, Cazenave-Gassiot A, Karasek P, Novotny I, Greplova K, Hrstka R, Holcapek M. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat Commun. 2022 Jan 10;13(1):124. doi: 10.1038/s41467-021-27765-9.